Shares of Moderna Inc. MRNA,
rose 1.3% in pre-trade on Monday after the company said it planned to launch new development programs using its mRNA technology, which focuses on developing vaccines for seasonal flu, HIV and the Nipah virus. This follows the success of his mRNA COVID-19 vaccine, which is one of two vaccines approved so far by the US CEO, and Moderna also said that he intends to expand his respiratory synthesis virus to older adults, and he plans to test different vaccine combinations that fight the flu, COVID-19, RSV and human metapneumovirus. “The uniquely challenging year of 2020 for society as a whole was an extraordinary proof-of-concept period for Moderna,” CEO Stéphane Bancel said in a news release. As part of the corporate update, Moderna said it has about $ 5.2 billion in cash on Dec. 31, compared to the $ 1.2 billion in cash it had the same year a year ago, and he expects at least $ 11 , 7 billion in revenue. in 2021 for its COVID-19 vaccine based on pre-purchase agreements. Moderna’s share has risen by 489.1% over the past year, while the S&P 500 SPX,
is 19.7% higher.
